Altamira Therapeutics Ltd. (CYTO) has an overall financial health rating of C with a composite score of 0 out of 5.
This suggests the company faces some financial challenges worth monitoring. Rating as of 2024-12-19.
| Date | Rating | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|
| 2024-12-19 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2024-12-18 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2024-12-17 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2024-12-16 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2024-12-12 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2024-12-11 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2024-12-10 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2024-12-09 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2024-12-06 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2024-12-05 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2024-12-04 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 | |
| 2024-12-03 | -/5 | -/5 | -/5 | -/5 | -/5 | -/5 |
